15 November - 16 November 2021

3rd SCI-RSC symposium on antimicrobial drug discovery

Organised by:

SCI’s Fine Chemicals Group and RSC’s Biological and Medicinal Chemistry Sector

Online webinar: 14:00 GMT(consecutive afternoons)

Register your Interest

At a time when antimicrobial resistance is decreasing the efficacy of existing treatments, it has never been more important that we refresh the drug pipeline with new therapeutics acting on new targets or exhibiting novel modes of action.
Fortunately, renewed interest from both industry and academia has led to a resurgence in antimicrobial drug discovery and interest in developing innovative technologies and approaches for combating infection.

Coinciding with WHO’s World Antibiotics Awareness week, this two-day meeting will examine the latest advances in antimicrobial drug discovery from a medicinal chemist’s perspective, focusing on the particular challenges associated with developing antimicrobials whilst also showcasing emerging strategies for tackling infection.


Call for Posters and Flash Presentations 
Anyone wishing to present a poster should submit a one-page abstract to conferences@soci.org by Friday 10 September 2021 with "AM-III – poster abstract" in the subject line. Selected poster presenters will have the opportunity to give a flash presentation.

Bringing together leading exponents in the field from industry and academia, the meeting will appeal to anyone with an interest in antimicrobial resistance and antimicrobial drug discovery.  And with great opportunities for academic–industrial partnerships, researchers from both sectors will also benefit from the networking opportunities that the meeting will offer.


Prof Anita Shukla

Brown University

Anita Shukla is an Assistant Professor of Engineering at Brown University. Her research involves development of nano- to macroscale biomaterials for treatment of microbial infections. Professor Shukla is the recipient of a Presidential Early Career Award for Scientists and Engineers (PECASE), a National Science Foundation CAREER award, an Office of Naval Research Director of Research Early Career Grant, and a Brown Early Career Research Achievement Award. Prior to joining Brown in 2013, she was a postdoc in Bioengineering at Rice University. She earned her Ph.D. in Chemical Engineering and M.S. in Chemical Engineering Practice from the Massachusetts Institute of Technology.

Prof Anna K. H. Hirsch

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Prof. Anna K. H. Hirsch obtained her M. Sci. from the University of Cambridge and her Ph.D. from the ETH Zurich in 2008 under Prof. F. Diederich. After a postdoc in Prof. J.-M. Lehn’s group, she became assistant professor at the University of Groningen in 2010 and associate professor in 2015.
In 2017, she became head of the department “Drug Design and Optimization” at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and full professor at Saarland University. She focuses on target-based anti-infective drug discovery, recognized by numerous prizes such as the Innovation Prize for Medicinal Chemistry of the GdCh/DPhG.

Dr Erin Duffy


Erin Duffy is the Chief of Research & Development at CARB-X. CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With up to US$480 million to invest in 2016-22, CARB-X funds the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections. Prior to CARB-X, she worked at Melinta Therapeutics (fka Rib-X Pharmaceuticals) for 17+ years, where she became EVP, Chief Scientific Officer, leading the research and early development activities of the Company. She began her industrial career at Pfizer Central Research. Erin holds a Ph. D. from Yale University in physical-organic chemistry.

Prof Gerry Wright

McMaster University

Gerard (Gerry) Wright is the Director of the Michael G. DeGroote Institute for Infectious Disease Research and the David Braley Centre for Antibiotic Discovery and the academic lead of Canada’ Global Nexus for Pandemics and Biological Threats. He is a Professor in the Department of Biochemistry and Biomedical Sciences at McMaster University and holds the Michael G. DeGroote Chair in Infection and Anti-Infective Research. His research interests are in the origins and mechanisms of antibiotic resistance and the discovery of new anti-infective strategies, in particular focusing on the application of microbial natural products and synthetic biology towards this goal.

Dr Thomas Durand-Reville

Entasis Therapeutics

Dr Durand-Reville obtained his Ph.D. in chemistry in 2000 in Paris. He then completed a postdoc in total synthesis at the University of Cambridge. Dr Durand-Reville started his US career at Biogen and Wyeth where he worked on several oncology and inflammation projects. Then, in the AstraZeneca Infection group, he was responsible for the medicinal chemistry strategy on many programs from early stage hit identification through IND-enabling studies, including durlobactam (now in Ph3). At Entasis Therapeutics, his group is currently focused on delivering a portfolio of innovative new antibiotics against multidrug-resistant Gram-negative pathogens, including ETX0282 (Ph1) and ETX0462 (GLP tox).


Monday 15 November

Opening remarks
Talk tbc
Talk tbc
Talk tbc
Talk tbc
Flash presentations

Tuesday 16 November

Opening remarks
Talk tbc
Talk tbc
Talk tbc
Talk tbc
Closing remarks

Confirmed speakers and sessions: 

Addressing unusual anti-infective targets, Prof Anna Hirsch, Helmholtz Institute of Pharmaceutical Research, Saarland, Germany

Discovery of ETX0462, a novel non-beta-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa, Dr Thomas Durand-Reville, Entasis Therapeutics, MA, USA

The truth is out there: Nature as a source of new antimicrobials and alternatives, Prof Gerry Wright, McMaster University, Canada

Tethered macrocyclic peptides, a novel antibiotic class targeting Acinetobacter baumannii, Dr Patrizio MatteiRoche, Switzerland

Addressing unusual anti-infective targets, Prof Anna Hirsch, Helmholtz Institute of Pharmaceutical Research, Saarland, Germany

Smart Biomaterials for the Treatment of Fungal and Bacterial Infections, Prof Anita Shukla, Brown University, USA

More speakers will be announced in due course.

Booking Process/Deadlines

Booking terms and conditions



Organising Committee
  • Dr Liam Cox, SCI / University of Birmingham
  • Dr Caroline Low, SCI / Computational Medicinal Chemistry Consultant
  • Dr Pascal Savy, SCI / Charles River Laboratories
  • Dr Francis Wilson, RSC / Summit Therapeutics

For further information and prices, please email conferences@soci.org

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org